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To assess and evaluate patient safety incidents and in particular, medication errors, during a 
large multi-centre pre-hospital trial of emergency therapy (PARAMEDIC2), in order to inform 
and improve future pre-hospital medicines trials. 
Methods 
The PARAMEDIC2 trial was undertaken across five NHS Ambulance Services in England and 
Wales with randomisation between December 2014 and October 2017. Patients with an out 
-of-hospital cardiac arrest unresponsive to initial resuscitation were randomly assigned to 1 
mg intravenous adrenaline or matching placebo. Records were reviewed to identify trial 
medication errors involving documentation and/or clinical protocol errors occurring in trial 
participants. Causes of medication errors, including root cause analysis where available, 
were reviewed to identify patterns and themes contributing to these errors. 
Results 
8,016 patients were enrolled, of whom 4902 received trial medication. 'A total of 331 
patient safety incidents was reported, involving 295 patients, representing an overall rate of 
3.6% Of these, 166 (50.2%) were documentation errors while 165 (49.8%) were clinical 
protocol/medication errors. An overall rate of 0-4.5% was reported across all five 
ambulance services, with a mean of 2.0%. These errors had no impact on patient care or the 
trial and were all resolved 
Conclusion 
The overall medication error rate of 1.8 % primarily consisted of administration of open-
label adrenaline and confusion with trial medication packs. A similar number of patients had 
documentation errors. This study is the first to provide data on patient safety incidents 
relating to medication errors encountered during a pre-hospital trial of emergency 
medication administration and will provide supporting data for planning future trials in this 
area. 
 
Abstract word count: 259  
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Introduction 
Clinically significant patient safety incidents (PSI) are defined as any unintended or unexpected 
incident, which could have or did lead to harm for one or more patients receiving NHS care. Within 
this classification, medication errors are defined as any PSI where there has been an error in the 
process of prescribing, preparing, dispensing, administering, monitoring or providing advice on 
medicines. A 2018 report estimated that 237 million medicine errors occur in England each year, and 
nearly 28% of these were clinically significant, having the potential to cause moderate or severe 
harm.2 In this report, medicine errors were identified at all stages of the medicines use process, the 
proportions being prescribing (21.3%), transition (1.4%), dispensing (15.9%), administration (54.4%) 
and monitoring (6.9%).  A recent review has identified an overall 10% intravenous medication error 
rate in hospitals during routine clinical care (101 intravenous medication errors per 1000 
administrations (95% CI 84 to 121)), with 32% of the errors overall occurring during medication 
administration.3  Paramedic drug prescribing and administration is different from hospital practice, 
as most paramedics are only authorised to administer drugs under Patient Group Directives and do 
so without a written prescription.  Nevertheless, data for pre-hospital administration is comparable, 
with error rates of 9-13% reported from two small retrospective studies, one of which was limited by 
self-reporting.4 5 Medication errors are likely to be greater during emergency or time-pressured 
situations, which act to accentuate human factors and compound stress-related errors. 
Interruptions, multi-tasking, and fatigue occurring in the Emergency Department are all associated 
with medication administration errors6 7 and pre-hospital studies have also identified workload and 
long evacuation times as risk factors for errors.5 Medicine errors have also been reported in clinical 
trials, but little is known about the prevalence or types of these errors.  Published data mostly 
relates to hospital-based trials,8 but medication errors in pre-hospital trials have not been reported.   
Patient safety and the integrity of a clinical trial depends on adherence to strict and specific 
protocols. Deviation from the trial protocol risks patient harm and the integrity of the trial, 
decreases the power of the study and ultimately jeopardises the ability of the research to deliver 
meaningful results.  The processes for the safe management of medicines in clinical trials are not 
standardised, and this presents risks.9 Clinical trials in the pre-hospital environment present specific 
challenges that are not seen elsewhere and these challenges are likely to be compounded by the 
administration of medicines in an emergency.  
Understanding patient safety incidents that occur in the pre-hospital setting will provide valuable 
data with which to plan future trials.  Information can be used to inform trial protocols and training 
strategies that minimise medication errors and also to understand the potential for medication 
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errors to reduce the magnitude of expected treatment effects and thus potentially reduce the power 
of a trial. The recent UK-based PARAMEDIC2 trial was a randomised, double-blind, trial comparing 
adrenaline with placebo during out-of-hospital cardiac arrest (OHCA).10, 11 The aim of the study was 
to investigate if adrenaline is beneficial or harmful for both short and long-term survival following 
OHCA. Having recruited 8,014 OHCA patients, it is the largest published pre-hospital clinical trial of 
an investigational medical product (CTIMP) in cardiac arrest. Trial procedures and oversight resulted 
in review of every patient recruited to the study, with particular focus on trial medication 
administration and protocol adherence.  This enabled identification of all patient safety incidents 
and an analysis of the type and cause of each error.  This study therefore provided a unique 
opportunity to also assess and evaluate medications incidents during a large multi-centre pre-
hospital trial of emergency therapy, in order to inform and improve future pre-hospital medicines 





The PARAMEDIC2 trial enrolled 8014 patients with OHCA, refractory to initial treatments across from 
5 regional ambulance services across England and Wales.  Participants were administered either IV 
adrenaline (4015 patients) or IV placebo (0.9% saline) (3999 patients), along with standard care. 
Bespoke treatment packs contained 10 pre-filled 3-ml syringes.  Each syringe contained a 1 mg dose 
of adrenaline or 0.9% saline.  Treatment packs and syringes contained brief information about the 
trial and a unique identifying number but were otherwise identical in appearance, thus masking 
treatment allocation from patients and clinicians.   
 
Clinical staff participating in the trial undertook a training package delivered locally by trial 
researchers, which involved either participation in either a DVD-based training package, or 
face-to-face training supplemented by e-learning. The training covered the key elements of 
the protocol related to enrolment of patients, administration of trial medications and 
principles of Good Clinical Practice.  All those completing training then undertook a local 
assessment. The detailed methodology has been described previously.11  
 
Protocol deviations, violations and serious breaches 
Any deviations, or violations of either the trial protocol or Good Clinical Practice (GCP) regulations12 
were reported to the WCTU trial team. These were defined and managed in accordance with the 
Trial Standard Operating Procedures. All reports were assessed by the trial team on the day of 
receipt, or the following working day if received on a weekend, and escalated to the Chief 
Investigator (or their delegate), Quality Assurance Team and WCTU Head of Operations if the non-
compliance was a new or exceptional event. All non-compliances, including cumulative numbers, 
trends and frequency over time, were reviewed at monthly Trial Management meetings. 'The TMG 
reviewed and allocated each report to one of the following categories of patient safety incident': 
 Documentation error: An unintentional recording error, which upon investigation was not 
associated with a deviation or violation of the clinical protocol.  
 Protocol Deviation: A change or departure from the protocol and/or GCP that does not 
result in harm to the study participants or significantly affect the scientific value of the 
reported results.  This may be an unintentional error or a deliberate deviation from the 
protocol, usually due to clinical reasons. 
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 Protocol Violation: A failure to comply with or variance from GCP and/or the final protocol. 
A violation is a serious non-compliance with the approved protocol resulting from error, 
fraud or misconduct.  
 Serious Breach: A non-compliance that is likely to affect to a significant degree the safety or 
physical or mental integrity of the study participants; and/or the scientific value of the study.  
All violations and serious breaches were immediately reported to the Sponsor (University of 
Warwick), and serious breaches were reported to the MHRA within seven days. The Sponsor, WCTU 
and ambulance service trial teams put in place corrective and preventative actions to mitigate the 
risk, and these actions were reviewed by the WCTU trial team to ensure all actions had been 
completed.  
 
In addition to monthly reviews, protocol violations were monitored using graphical plots. The 
monthly number of violations and the proportion as a percentage of recruitment were plotted. The 
moving range, defined as the absolute value of month-to-month change, was plotted against the 
recruitment month. Any out-of-control conditions, defined as outside the pre-specified limits, were 
investigated for quality control.  
 
Events involving medication errors were further classified (a) and details of controls in place to 
prevent these from occurring also listed (b) : 
 Documentation errors  
a) Errors where the medication administration itself was correct but the written record of 
medication administration was incorrect (e.g. trial pack number was not recorded, the 
wrong code was recorded on paperwork or the administration of the trial medicines was not 
notified to the trial team). 
b) Investigations were carried out to confirm correct pack numbers and cross checks were 
made by research paramedics, according to local process, usually including Patient Report 
Forms (PRFs), drug logs and other local reporting mechanisms (text, voice message system). 
Retraining was provided where errors were found, together with aide memoirs and 
reminders via internal newsletters and posters. 
 Ineligible patients enrolled: 
a) Patients enrolled who did not meet the trial inclusion criteria (Cardiac arrest in out of 
hospital environment and advanced life support initiated and / or continued by ambulance 
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service clinician) or those who were enrolled but met one of the exclusion criteria (known or 
apparent pregnancy, known or apparently aged under 16 years, cardiac arrest caused by 
anaphylaxis or life threatening asthma, or adrenaline given prior to arrival of ambulance 
service clinician). 
b) Research paramedics checked PRFs to confirm eligibility. A full investigation into cases 
where confirmed ineligible patients enrolled was carried out, together with a debrief with 
the attending ambulance crew. Additional labelling was also added to trial drugs to highlight 
eligibility criteria, with reminders sent to ambulance crew via internal newsletters and 
posters. 
 Open label adrenaline given:  
a) Patients in whom standard adrenaline was administered rather than the trial medication. 
b) In each case, retraining was provided to individuals concerned and reminders added to 
posters, aide memoirs and newsletters. 
 One pack – two patients:  
a) Cases in which one pack of trial medications (containing ten syringes of adrenaline and/or 
placebo) was administered to two successive patients in cardiac arrest. 
b) In each case, retraining was provided to individuals concerned and reminders added to 
posters, aide memoirs and newsletters. 
 Two packs – one patient:  
a) Cases in which two trial packs were opened at a cardiac arrest and medications from both 
packs potentially administered to the patient. 
b) Additional trial drug labelling. 
 Expired pack used:  
a) Cases in which time-expired medication was administered. (The decision to categorise the 
use of an expired pack as a deviation or violation was based on whether the pack was used 
within the 12-month shelf life.) 
b) Advice was sought from the manufacturer’s Qualified Person to confirm stability of product. 
Clear recall process of trial drug in pre-hospital setting. Packs unaccounted for were tracked 
by research paramedics, alerts were made to regional managers, and a process for reporting 
expired packs to research paramedics was put in place. 
 Wrong pack:  
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a) Patients where medication administered was not taken from the allocated trial pack. (A pack 
not allocated by the randomisation process). 
b) In each case, retraining was provided to individuals concerned and reminders added to 
posters, aide memoirs and newsletters. 
 
All protocol medication non-compliance events occurring during the study period were collated and 









There were 331 medication errors among the 8106 trial patients over the three-year study period. This total included a subset of 166 documentation 
errors. An overall rate of 0 - 4.5% was reported across all five ambulance services, with a mean of 2.0%. These errors had no impact on patient care or the 
trial and were all resolved. Medication errors classified as ‘missing’ refer to drug trial packs that went missing, so it was not possible to determine whether 
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Inadvertent recruitment of patients who met exclusion criteria are listed in Table 2, together with 






Root cause analysis 




Drug prepared by non-trial 
trained staff 
Pregnancy 1 1*  
 
0 0 
Anaphylaxis  6 3* 3 0 





2 1  1 
 
* Patients withdrawn and open label adrenaline administered when clinician became aware of 
exclusion.  ** 4 patients withdrawn as possibility of asthma identified after enrolment but during on-
going treatment.  
 
Table 2: Ineligible patients enrolled 
 
 
In 57 patients, open-label adrenaline rather than trial medication was administered at the initial 
cardiac arrest when the patient was entered in to the trial. The reasons for open-label 
administration are listed in table 3. 
 
Reason n= 
Trial pack finished and more adrenaline needed 14 
Re-arrest 5 
Other clinician took over/multiple providers  31 
Post-ROSC adrenaline then re-arrest 4 
Adrenaline for asthma then trial med 1 
Two trial packs given then recognised error so adrenaline given 1 
Reason unknown 1 
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Table 3: Open label adrenaline administered to patients enrolled in trial 
 
The total number of protocol violations occurring each month during the trial period are shown in 






A total of 331 errors were reported involving 295 patients, during the recruitment and enrolment of 
8106 trial patients, representing an overall error rate of 3.6%.with some patients experiencing more 
than one event. Of these, 166 (50.2%) were documentation errors whilst 165 (49.8%) were clinical 
protocol/medication errors.  This is the first reported analysis of medication errors during a clinical 
trial in the pre-hospital emergency environment, and provides data to establish a baseline of the 
prevalence and types of errors that may occur when conducting medication trials in this setting. The 
medication errors we describe consist of those occurring as a result of medication administered 
during the stress of emergency and time-critical therapy, compounded by the additional 
complexities of medication administration as part of a trial protocol. Errors occurred at all stage of 
medication administration, but were particularly common in relation to the retrospective 
documentation, and accounted for approximately half of all errors. Administration of open-label 
adrenaline was the largest single cause of medication-related error (18.5%), but confusion about the 
actual trial medication packs (expired pack, multiple packs opened etc) accounted for almost as 
many errors (15.4%). Although trial exclusion criteria varied from the usual indication for adrenaline 
administration during cardiac arrest, which had the potential to cause confusion, relatively few 
incidents of enrolment of ineligible patients were reported (19/324; 5.9%). This low rate may have 
been achieved by having a large, clear label attached to the trial medications listing exclusion 
criteria.  
The training package for paramedics taking part in the trial included emphasis on the equivocal 
evidence for adrenaline, particularly in relation to long-term neurological outcomes. This focus on 
explaining the rationale for the trial to paramedics may have contributed to the relatively low rates 
of intentional non-compliance than seen in previous trials.13 Greater rates of non-compliance were 
seen when clinical management was taken over by those not familiar with, or trained in, the trial. On 
occasion, senior staff not trained in the trial protocol overrode the decision of trained staff in the 
decision to recruit a patient to the trial.  Of the 60 cases of medication errors when open label 
adrenaline was administered, 19 cases occurred when non-trial clinicians became involved in the 
medication decision-making process once trial enrolment had occurred, resulting in a deviation of 
the trial protocol.  
Exclusion criteria in clinical trial are usually due to regulatory / trial based reasons or because there 
is a contraindication or rationale for why a particular patient group should not be involved.  In 
PARAMEDIC2 we excluded patients for regulatory / trial related reasons who were known to be 
pregnant or aged less than 16 years. The rationale for excluding these groups was the infrequency of 
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cardiac arrest events in these populations, different causes and outcomes of cardiac arrest, 
insurance considerations and in addition for children, different models for obtaining consent and 
different tools to record neurological outcomes.  Patients with suspected anaphylaxis were excluded 
due to the theoretical benefits of mast cell stabilising effects of adrenaline,14 although no clinical 
trial evidence exists to support adrenaline use during cardiac arrest in this setting.15  The literature in 
relation to safety and effectiveness of adrenaline in cardiac arrest due to asthma is also lacking. 
Indirect evidence suggests the potential for both benefit and harm in this group.16 Given the 
potential for overlap in the clinical presentation of asthma and anaphylaxis, and relative infrequency 
of this type of cardiac arrest, the trial team took the pragmatic decision to exclude this patient 
group.  Enrolment of ineligible patients nevertheless requires careful review and scrutiny.  In 
PARAMEDIC2 a root cause analysis was undertaken for each case and corrective and preventative 
actions taken.  Across these detailed reviews two key themes emerged (1) failure to recognise that 
the patient had the condition at the time of enrolment (2) failure to remember the specific 
exclusions at the time of enrolment.  In these cases, the existing preventative measures (protocol 
training, presence of trial exclusion criteria on the outside of the treatment packs and labels on the 
syringes, were insufficient to prevent enrolment in error.  Whether alternative approaches such as 
the use of checklists, or verbal challenge, already proven in the surgical environment,17 would be 
practicable and reduce error remains to be determined.    
 
With regular exposure to the trial protocol, we believed that the rate of medication errors might 
have declined as the trial progressed. However, the majority of paramedics respond to no more than 
1-2 cardiac arrests annually,18 so individual exposure to the trial was relatively infrequent. This may 
explain why there was little change in the overall rate of medication errors over the duration of the 
trial (Figure 1).  There was a wide variation in errors occurring across the five ambulance services 
participating in the study, both in terms of type of error and absolute numbers.  Overall error rates 
between ambulance services ranged from 1.7% to 7.1%. This variation in error rate between 
ambulance services was represented in errors across all categories. Errors between ambulance 
services are likely to reflect a variation in internal policies and procedures, composition of clinical 
resources on scene, variation in refresher training in resuscitation, cultural approaches to 
participating in research, or a different reporting culture.19 The higher rate of reporting from one 
ambulance service may reflect a higher error rate, an increased level of awareness of safety or a 
more open and transparent reporting culture.  The participating ambulance services had agreed 
different local processes to deliver the trial. This was designed to help the trial integrate with local 
established logistical processes. Unfortunately, it is not possible to identify whether these different 
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processes had an impact on these subsequent medication errors.  A systematic review of medication 
errors in adult intensive care documented variation in local processes but did not find evidence to 
support the benefit of any particular intervention to reduce medication errors; these included 
changes in work schedules, modes of education, protocols and guidelines and support systems for 
clinical decision making.20 
Factors specific to the clinical setting and the treatment being administered may reduce trial 
protocol compliance and contribute to errors.  Twelve of the 60 open label adrenaline administered 
errors were attributed to a ‘chaotic’ environment. This is consistent with reports that clinical error 
rates in the emergency department increase almost threefold when physicians are interrupted.6 
Interruptions are often cited as a problem in medication safety, particularly in relation to nurses 
administering medication,21 though these errors are generally related to the time of administration 
of the medicine and the rate of administration,7 both of which are not applicable to this study. 
This report presents a summary of cases where patients did not receive the trial medication as 
anticipated in the trial protocol, which has occurred as a result of both medication errors where 
actions are intended but not performed, and deviations from trial protocol where the treating 
clinician considered it in the patient’s best interest (correctly or otherwise) to deviate from the trial 
protocol. Considering the frequency with which medication errors occur, the potential for patient 
harm and the impact on the validity and integrity of research studies involving medication 
administration, there is surprisingly little published in the literature about medication errors.  A 
number of studies have examined factors associated with medication errors.22 Some are general 
factors associated with all prescribing (e.g. lack of therapeutic training, inadequate drug knowledge 
and experience, prescribing systems that allow for human error, confirmation bias etc), but others 
are factors specifically relating to time-critical, emergency situations which together can cause 
cognitive overload. Workload and time pressures, distractions and interruptions, lack of 
standardized protocols and procedures, and insufficient resources are all major contributors to the 
risk of medication errors.22 The pre-hospital environment also adds further contributory factors not 
present in the hospital environment. The physical environment was among the top five factors 
contributing to medication errors.23. and challenges with the physical work environment (e.g., 
lighting, temperature and ventilation) are particularly prevalent when dealing with patients in 
cardiac arrest. 
 
Overall, the number of medication errors of 3.6% reported in this trial is relatively low. A review of 
studies of medicine administration errors, mainly from the US and the UK found a median error rate 
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of 8.0% (5.1-10.9%).24 More errors were observed for the intravenous route (53.3%) where each 
dosing error could accumulate more than one error. A previous study reporting medication errors 
during a cancer medication trial similarly reported that approximately half of all medication errors 
did not involve medication delivery to the patient.25 An observational study of prescribing errors by 
emergency physicians in Australia found on average 0.4 clinical prescribing errors per patient and 2.6 
legal/procedural errors per patient, with 60% of medicine prescriptions having 1 or more errors.6 
Most errors were insignificant (94.2%) and the remainder were of moderate severity. The number of 
errors reported in this Australian study was significantly less, mostly likely because the trial involved 
a short and very specific patient care episode. The relatively few errors reported in this study may be 
in part because only one patient was being managed at a time, using a limited number of medicines, 
as previously reported.4 Additional training for trial paramedics, together with anticipated close 
observation and scrutiny of the trial patients may also have contributed to fewer errors. There may 
also be underreporting of procedural errors, as it appears that most were reported by one of the five 
ambulance services involved in the study.  Previous medicine trials have found that the majority of 
medication errors are corrected before the medication is administered to the patient, or they do not 
result in patient harm.25 This is consistent with our findings. The most common cause of error was 
not following the procedure or the protocol, which may be both due to a lack of understanding or an 
intentional decision,26 compounded by the infrequent exposure to OHCA by individual paramedics.  
 
The causes and contributory factors to medication errors should be considered during the trial 
design process. Interruptions during pre-hospital care should be minimised, but the pre-hospital 
setting may make this difficult. Communication tools should be considered because good 
communication plays a role in reducing medication errors. This should include communication with 
clinicians who are present but who have not been trained in, or are unaware of, the trial. Previous 
studies have documented errors related to  fatigue, clinical workload and stress, compounded by 
interuptions to adminstration of trial medication and multi-tasking. It is clear therefore that 
improvements in drug error rates will be achieved by ensuring cardiac arrest teams are well 
reheared and practiced in the delivery of this protocol-driven task. The move towards pre-hospital 
electronic recording of clinical care is likely to reduce overall workload and improve documentation 
errors, ensuring more accurate recording of drug administration. Future medication trials should 
routinely report medication errors so that trial design can be continually improved. Consideration 
should be given to standard methods of error classification, as this will enable comparison between 
sites and between trials. However, there is some inconsistency with the published classification of 
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errors which could also be addressed in future research.  Clinicians must be encouraged to report all 
errors and near misses, so that learning can take place.  
 
Conclusion 
In this pre-hospital randomised clinical trial of 8106 patients, we documented a relatively low overall 
medication error rate of 1.8 %. Errors in relation to documentation accounted for approximately half 
of all errors, with the remainder primarily consisting of those relating to administration of open-label 
adrenaline and confusion with trial medication packs. There was little change in the overall rate of 
medication errors over the four-year duration of the trial, possibly due to the relative infrequency 
with which individual paramedics enrolled patients into the trial. This study is the first to provide 
data on medication errors encountered during a pre-hospital trial of emergency medication 
administration and will provide supporting data for planning future trials in this area.  
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